Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.40 Consensus Target Price from Analysts

Cardiol Therapeutics Inc. (NASDAQ:CRDL) has earned an average rating of “Buy” from the seven analysts that are covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $8.40.

Several research firms have recently weighed in on CRDL. RODMAN&RENSHAW raised shares of Cardiol Therapeutics to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw began coverage on Cardiol Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $7.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Cardiol Therapeutics in a report on Wednesday, April 16th.

Cardiol Therapeutics Trading Up 0.9 %

NASDAQ CRDL opened at $1.15 on Thursday. Cardiol Therapeutics has a 52 week low of $0.77 and a 52 week high of $3.12. The company has a 50 day moving average price of $1.04 and a 200 day moving average price of $1.31. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. The firm has a market cap of $95.00 million, a PE ratio of -2.95 and a beta of 0.98.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. As a group, sell-side analysts forecast that Cardiol Therapeutics will post -0.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Cardiol Therapeutics

Institutional investors have recently bought and sold shares of the company. Jones Financial Companies Lllp acquired a new position in Cardiol Therapeutics during the fourth quarter worth about $25,000. Jane Street Group LLC purchased a new stake in shares of Cardiol Therapeutics in the 3rd quarter valued at approximately $29,000. Cetera Investment Advisers acquired a new stake in shares of Cardiol Therapeutics during the 4th quarter worth approximately $56,000. Virtu Financial LLC purchased a new stake in shares of Cardiol Therapeutics during the 4th quarter valued at approximately $61,000. Finally, Atria Investments Inc acquired a new position in shares of Cardiol Therapeutics in the 4th quarter valued at $174,000. 12.49% of the stock is currently owned by institutional investors and hedge funds.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.